This is a small, routine sale by a former director following an option exercise. No material impact expected. Monitor for any larger insider sales ahead of upcoming catalysts.
VIR drugs
VIR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $10.38entry
- T+1 · 5mo ago −1.83%α −2.61% · $10.19
- T+5 · 4mo ago −3.47%α −4.86% · $10.02
- T+20 · 4mo ago −16.28%α −16.00% · $8.69
- T+60 · 8w ago +6.84%α +3.22% · $11.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Former director Saira Ramasastry filed a Form 144 on June 29, 2026, indicating intent to sell 16,000 shares of Vir Biotechnology (VIR) with an approximate market value of $165,139. The sale follows a stock option exercise and represents a routine diversification move by a former board member, not a current executive. Given the small size relative to VIR's $1.7B market cap and the insider's former-director status, the signal is minimal.
Key Facts
- Insider: Saira Ramasastry, former director
- Shares to be sold: 16,000 shares of common stock
- Estimated value: ~$165,139
- Source of shares: stock option exercise (issuer grant)
- Broker: Fidelity Brokerage Services LLC
- Filing date: June 29, 2026
Financial Impact
Sale of 16,000 shares valued at ~$165K, representing less than 0.01% of VIR's $1.7B market cap
Risk Factors
- Insider selling could increase if more directors or executives file similar notices
- Option exercise may signal limited upside conviction from this insider
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004947 |
| Document: 0001959173-26-004947-index.html | 0001959173-26-004947 |
| Document: 0001959173-26-004947.txt | 0001959173-26-004947 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers